Quarterly ResultMay 7, 2026, 04:03 PM
Amneal Q1 Net Revenue $723M, Net Income $62M, EPS $0.19
AI Summary
Amneal Pharmaceuticals, Inc. announced strong first quarter 2026 results, with net revenue reaching $723 million, a 4% increase year-over-year. GAAP net income surged by 411% to $62 million, and diluted income per share rose by 375% to $0.19. The company also reported a 19% increase in Adjusted EBITDA to $202 million and a 29% rise in Adjusted Diluted EPS to $0.27, affirming its previously announced increased full-year 2026 guidance.
Key Highlights
- Q1 2026 Net Revenue was $723 million, an increase of 4% compared to Q1 2025.
- Q1 2026 GAAP Net Income was $62 million, an increase of 411% YoY.
- Q1 2026 Diluted Income per Share was $0.19, an increase of 375% YoY.
- Q1 2026 Adjusted EBITDA was $202 million, an increase of 19% YoY.
- Q1 2026 Adjusted Diluted EPS was $0.27, an increase of 29% YoY.
- Specialty net revenue increased 23%, driven by CREXONT and BREKIYA autoinjector.
- Affordable Medicines net revenue increased 2%, driven by complex portfolio performance.
- Company affirmed 2026 full-year guidance: Net revenue $3.05B-$3.15B, Adjusted EBITDA $740M-$770M, Adjusted diluted EPS $0.95-$1.05.